The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Immune escape and immunotherapy of acute myeloid leukemia
Open accessAbstract
In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales. It is increasingly evident that the bone marrow immune environment of AML patients is profoundly altered, contributing to the severity of the disease but also providing several windows of opportunity to prompt or rewire a proficient antitumor immune surveillance. In this Review, we present current evidence on immune defects in AML, discuss the challenges with selective targeting of AML cells, and summarize the clinical results and immunologic insights from studies that are testing the latest immunotherapy approaches to specifically target AML cells (antibodies, cellular therapies) or more broadly reactivate antileukemia immunity (vaccines, checkpoint blockade). Given the complex interactions between AML cells and the many components of their environment, it is reasonable to surmise that the future of immunotherapy in AML lies in the rational combination of complementary immunotherapeutic strategies with chemotherapeutics or other oncogenic pathway inhibitors. Identifying reliable biomarkers of response to improve patient selection and avoid toxicities will be critical in this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · cited 1×
“Similarly, increased frequency of functionally exhausted CD8+ T cells coexpressing the CIRs PD-1 and TIM3 coincided with disease progression in a mouse model of AML; these cells’ cytotoxic function was reinvigorated by combined checkpoint inhibition (64).”
BackgroundBurnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y.-B., McSweeney, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 593
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 555
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation
Vago, L., Perna, S. K., Zanussi, M., Mazzi, B., Barlassina, C., Stanghellini, M. T. L., Perrelli, N. F., Cosentino, C., Torri, F., Angius, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0811036 · Cited by 529
Self-citationGill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
Christopher, M. J., Petti, A. A., Rettig, M. P., Miller, C. A., Chendamarai, E., Duncavage, E. J., Klco, J. M., Helton, N. M., O’Laughlin, M., Fronick, C. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808777 · Cited by 463
Kim, M. Y., Yu, K.-R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T.-H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 459
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Tang, X., Yang, L., Li, Z., Nalin, A. P., Dai, H., Xu, T., Yin, J., You, F., Zhu, M., Shen, W., et al. (2018) · Europe PMC (PubMed Central) · Cited by 406
Walter, R. B., Gooley, T. A., Wood, B. L., Milano, F., Fang, M., Sorror, M. L., Estey, E. H., Salter, A. I., Lansverk, E., Chien, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8121 · Cited by 405
Goodyear, O. C., Dennis, M., Jilani, N. Y., Loke, J., Siddique, S., Ryan, G., Nunnick, J., Khanum, R., Raghavan, M., Cook, M., et al. (2012) · Blood · doi:10.1182/blood-2011-09-377044 · Cited by 401
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Toffalori, C., Zito, L., Gambacorta, V., Riba, M., Oliveira, G., Bucci, G., Barcella, M., Spinelli, O., Greco, R., Crucitti, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0400-z · Cited by 401
Self-citationCurti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036863 · Cited by 396
The Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T. (2007) · Blood · doi:10.1182/blood-2005-08-027979 · Cited by 380
Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., Hoffman, L., Aguilar, B., Chang, W.-C., Bretzlaff, W., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474056 · Cited by 374
Aberrant Overexpression of the Wilms Tumor Gene (WT1) in Human Leukemia
Inoue, K., Ogawa, H., Sonoda, Y., Kimura, T., Sakabe, H., Oka, Y., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., et al. (1997) · Blood · doi:10.1182/blood.v89.4.1405 · Cited by 371
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S. R., Morris, L. E., Holland, H. K., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 364
Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
Biton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 351
Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 346
Rezvani, K., Yong, A. S. M., Mielke, S., Savani, B. N., Musse, L., Superata, J., Jafarpour, B., Boss, C., & Barrett, A. J. (2008) · Blood · doi:10.1182/blood-2007-08-108241 · Cited by 341
Goodyear, O., Agathanggelou, A., Novitzky-Basso, I., Siddique, S., McSkeane, T., Ryan, G., Vyas, P., Cavenagh, J., Stankovic, T., Moss, P., et al. (2010) · Blood · doi:10.1182/blood-2009-11-249474 · Cited by 340
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
Mussai, F., De Santo, C., Abu-Dayyeh, I., Booth, S., Quek, L., McEwen-Smith, R. M., Qureshi, A., Dazzi, F., Vyas, P., & Cerundolo, V. (2013) · Blood · doi:10.1182/blood-2013-01-480129 · Cited by 332
Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer · doi:10.1002/cncr.31896 · Cited by 330 · cited 3×
“Relative to healthy controls (HCs), AML patients have a comparable number of T cells in BM and even higher levels of total and CD8+ PB T cells (58, 59).”
BackgroundBaumeister, S. H., Murad, J., Werner, L., Daley, H., Trebeden-Negre, H., Gicobi, J. K., Schmucker, A., Reder, J., Sentman, C. L., Gilham, D. E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0307 · Cited by 329
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Chapuis, A. G., Egan, D. N., Bar, M., Schmitt, T. M., McAfee, M. S., Paulson, K. G., Voillet, V., Gottardo, R., Ragnarsson, G. B., Bleakley, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0472-9 · Cited by 329
Chapuis, A. G., Ragnarsson, G. B., Nguyen, H. N., Chaney, C. N., Pufnock, J. S., Schmitt, T. M., Duerkopp, N., Roberts, I. M., Pogosov, G. L., Ho, W. Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004916 · Cited by 311
LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration
Deng, M., Gui, X., Kim, J., Xie, L., Chen, W., Li, Z., He, L., Chen, Y., Chen, H., Luo, W., et al. (2018) · Nature · doi:10.1038/s41586-018-0615-z · Cited by 305
Szczepanski, M. J., Szajnik, M., Czystowska, M., Mandapathil, M., Strauss, L., Welsh, A., Foon, K. A., Whiteside, T. L., & Boyiadzis, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3010 · Cited by 303
Kong, Y., Zhu, L., Schell, T. D., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., George, M. R., Zeng, H., & Zheng, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2626 · Cited by 297
Mathew, N. R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M., Müller, T. A., Hanke, K., Taromi, S., Apostolova, P., et al. (2018) · Nature Medicine · doi:10.1038/nm.4484 · Cited by 295
Self-citationPizzitola, I., Anjos-Afonso, F., Rouault-Pierre, K., Lassailly, F., Tettamanti, S., Spinelli, O., Biondi, A., Biagi, E., & Bonnet, D. (2014) · Leukemia · doi:10.1038/leu.2014.62 · Cited by 287
Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275446 · Cited by 287
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Specificity of T-cell alloreactivity
Felix, N. J., & Allen, P. M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2200 · Cited by 254
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 253
Le Dieu, R., Taussig, D. C., Ramsay, A. G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A. M., Lister, T. A., & Gribben, J. G. (2009) · Blood · doi:10.1182/blood-2009-02-206946 · Cited by 243
Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?
Ustun, C., Miller, J. S., Munn, D. H., Weisdorf, D. J., & Blazar, B. R. (2011) · Blood · doi:10.1182/blood-2011-07-365817 · Cited by 220
Sallman, D. A., Asch, A. S., Al Malki, M. M., Lee, D. J., Donnellan, W. B., Marcucci, G., Kambhampati, S., Daver, N. G., Garcia-Manero, G., Komrokji, R. S., et al. (2019) · Blood · doi:10.1182/blood-2019-126271 · Cited by 213
Knaus, H. A., Berglund, S., Hackl, H., Blackford, A. L., Zeidner, J. F., Montiel-Esparza, R., Mukhopadhyay, R., Vanura, K., Blazar, B. R., Karp, J. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120974 · Cited by 211
Self-citationKrupka, C., Kufer, P., Kischel, R., Zugmaier, G., Bögeholz, J., Köhnke, T., Lichtenegger, F. S., Schneider, S., Metzeler, K. H., Fiegl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-08-523548 · Cited by 208
MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia
Cobbold, M., De La Peña, H., Norris, A., Polefrone, J. M., Qian, J., English, A. M., Cummings, K. L., Penny, S., Turner, J. E., Cottine, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006061 · Cited by 204
Jetani, H., Garcia-Cadenas, I., Nerreter, T., Thomas, S., Rydzek, J., Meijide, J. B., Bonig, H., Herr, W., Sierra, J., Einsele, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0009-0 · Cited by 203
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 200
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
Pyzer, A. R., Stroopinsky, D., Rajabi, H., Washington, A., Tagde, A., Coll, M., Fung, J., Bryant, M. P., Cole, L., Palmer, K., et al. (2017) · Blood · doi:10.1182/blood-2016-07-730614 · Cited by 192
Gemtuzumab ozogamicin for acute myeloid leukemia
Appelbaum, F. R., & Bernstein, I. D. (2017) · Blood · doi:10.1182/blood-2017-09-797712 · Cited by 184
Lynn, R. C., Poussin, M., Kalota, A., Feng, Y., Low, P. S., Dimitrov, D. S., & Powell, D. J. (2015) · Blood · doi:10.1182/blood-2014-11-612721 · Cited by 182
Wang, L., Jia, B., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Mineishi, S., Naik, S., Khawaja, M. R., Sivik, J., Han, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1469594 · Cited by 180
Hughes, A., Clarson, J., Tang, C., Vidovic, L., White, D. L., Hughes, T. P., & Yong, A. S. M. (2017) · Blood · doi:10.1182/blood-2016-10-745992 · Cited by 178
Craddock, C., Jilani, N., Siddique, S., Yap, C., Khan, J., Nagra, S., Ward, J., Ferguson, P., Hazlewood, P., Buka, R., et al. (2016) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.09.004 · Cited by 175
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0465-9 · Cited by 173
Mechanisms of immune escape after allogeneic hematopoietic cell transplantation
Zeiser, R., & Vago, L. (2018) · Blood · doi:10.1182/blood-2018-10-846824 · Cited by 172
Self-citationTawara, I., Kageyama, S., Miyahara, Y., Fujiwara, H., Nishida, T., Akatsuka, Y., Ikeda, H., Tanimoto, K., Terakura, S., Murata, M., et al. (2017) · Blood · doi:10.1182/blood-2017-06-791202 · Cited by 171
Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia
Anguille, S., Van Tendeloo, V. F., & Berneman, Z. N. (2012) · Leukemia · doi:10.1038/leu.2012.145 · Cited by 168
Berthon, C., Driss, V., Liu, J., Kuranda, K., Leleu, X., Jouy, N., Hetuin, D., & Quesnel, B. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0909-y · Cited by 167
Norde, W. J., Maas, F., Hobo, W., Korman, A., Quigley, M., Kester, M. G. D., Hebeda, K., Falkenburg, J. H. F., Schaap, N., de Witte, T. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0108 · Cited by 167
Tasian, S. K., Kenderian, S. S., Shen, F., Ruella, M., Shestova, O., Kozlowski, M., Li, Y., Schrank-Hacker, A., Morrissette, J. J. D., Carroll, M., et al. (2017) · Blood · doi:10.1182/blood-2016-08-736041 · Cited by 167
Schnorfeil, F. M., Lichtenegger, F. S., Emmerig, K., Schlueter, M., Neitz, J. S., Draenert, R., Hiddemann, W., & Subklewe, M. S. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0189-2 · Cited by 165
Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 165
Kong, Y., Zhang, J., Claxton, D. F., Ehmann, W. C., Rybka, W. B., Zhu, L., Zeng, H., Schell, T. D., & Zheng, H. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.58 · Cited by 164
Rosenblatt, J., Stone, R. M., Uhl, L., Neuberg, D., Joyce, R., Levine, J. D., Arnason, J., McMasters, M., Luptakova, K., Jain, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1298 · Cited by 164
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Maslak, P. G., Dao, T., Bernal, Y., Chanel, S. M., Zhang, R., Frattini, M., Rosenblat, T., Jurcic, J. G., Brentjens, R. J., Arcila, M. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014175 · Cited by 161
Greiner, J., Ono, Y., Hofmann, S., Schmitt, A., Mehring, E., Götz, M., Guillaume, P., Döhner, K., Mytilineos, J., Döhner, H., et al. (2012) · Blood · doi:10.1182/blood-2011-11-394395 · Cited by 152
Crucitti, L., Crocchiolo, R., Toffalori, C., Mazzi, B. A., Greco, R., Signori, A., Sizzano, F., Chiesa, L., Zino, E., Stanghellini, M. T. L., et al. (2014) · Leukemia · doi:10.1038/leu.2014.314 · Cited by 148
Self-citationKittang, A. O., Kordasti, S. Y., Sand, K. E., Costantini, B., Kramer, A. M., Abellan, P. P., Seidl, T., Rye, K. P., Hagen, K. M., Kulasekararaj, A. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062208 · Cited by 148
Ravandi, F., Assi, R. E., Daver, N. G., Benton, C. B., Kadia, T. M., Thompson, P. A., Borthakur, G. M., Alvarado, Y., Jabbour, E. J., Konopleva, M. Y., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30114-0 · Cited by 147
Lu, T., & Gabrilovich, D. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2939 · Cited by 146
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L., Snyder, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.03.036 · Cited by 138
Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
Borot, F., Wang, H., Ma, Y., Jafarov, T., Raza, A., Ali, A. M., & Mukherjee, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819992116 · Cited by 135
Behl, D., Porrata, L. F., Markovic, S. N., Letendre, L., Pruthi, R. K., Hook, C. C., Tefferi, A., Elliot, M. A., Kaufmann, S. H., Mesa, R. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2404032 · Cited by 133
Arai, J. A., Yasukawa, M., Ohminami, H., Kakimoto, M., Hasegawa, A., & Fujita, S. (2001) · Blood · doi:10.1182/blood.v97.9.2903 · Cited by 132
Clinical significance of B7-H1(PD-L1)expression in human acute leukemia
Chen, X., Liu, S., Wang, L., Zhang, W., Ji, Y., & Ma, X. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5689 · Cited by 130
Aigner, M., Feulner, J., Schaffer, S., Kischel, R., Kufer, P., Schneider, K., Henn, A., Rattel, B., Friedrich, M., Baeuerle, P. A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.341 · Cited by 130
Zhang, T., Barber, A., & Sentman, C. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0130 · Cited by 128
Rezvani, K., Yong, A. S. M., Tawab, A., Jafarpour, B., Eniafe, R. B., Mielke, S., Savani, B. N., Keyvanfar, K., Li, Y., Kurlander, R. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144071 · Cited by 127
Herrmann, M., Krupka, C., Deiser, K., Brauchle, B., Marcinek, A., Wagner, A. O., Rataj, F., Mocikat, R., Metzeler, K. H., Spiekermann, K., et al. (2018) · Blood · doi:10.1182/blood-2018-05-849802 · Cited by 122
Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., Bertaina, V., Mastronuzzi, A., Gaspari, S., Zecca, M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1504 · Cited by 120
Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis
Stern, M., de Wreede, L. C., Brand, R., van Biezen, A., Dreger, P., Mohty, M., de Witte, T. M., Kröger, N. M., Ruutu, T., & for the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (2014) · Leukemia · doi:10.1038/leu.2014.145 · Cited by 120
Peinert, S., Prince, H. M., Guru, P., Kershaw, M. H., Smyth, M. J., Trapani, J. A., Gambell, P. C., Harrison, S. J., Scott, A. M., Smyth, F. E., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.21 · Cited by 118
Krönig, H., Kremmler, L., Haller, B., Englert, C., Peschel, C., Andreesen, R., & Blank, C. U. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12228 · Cited by 114
Aurelius, J., Thorén, F. B., Akhiani, A. A., Brune, M. L., Palmqvist, L., Hansson, M., Hellstrand, K., & Martner, A. (2012) · Blood · doi:10.1182/blood-2011-11-391722 · Cited by 113
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Dama, P., Tang, M., Fulton, N. C., Kline, J. P., & Liu, H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0611-3 · Cited by 113
Gutbrodt, K. L., Schliemann, C., Giovannoni, L., Frey, K., Pabst, T., Klapper, W., Berdel, W. E., & Neri, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006221 · Cited by 110
A novel self-lipid antigen targets human T cells against CD1c+ leukemias
Lepore, M., de Lalla, C., Gundimeda, S., Gsellinger, H., Consonni, M., Garavaglia, C., Sansano, S., Piccolo, F. M., Scelfo, A., Häußinger, D., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140410 · Cited by 109
Dutour, A., Marin, V., Pizzitola, I., Valsesia‐Wittmann, S., Lee, D. A., Yvon, E. S., Finney, H. M., Lawson, A. D. G., Brenner, M. K., Biondi, A., et al. (2012) · Advances in Hematology · doi:10.1155/2012/683065 · Cited by 105
Davids, M. S., Kim, H. T., Costello, C. L., Herrera, A. F., Locke, F. L., Maegawa, R., Savell, A., Mazzeo, M., Anderson, A., Boardman, A. P., et al. (2020) · Blood · doi:10.1182/blood.2019004710 · Cited by 105
Stasi, A. D., Jiménez, A., Minagawa, K., Al‐Obaidi, M., & Rezvani, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00036 · Cited by 104
Zeidan, A. M., Knaus, H. A., Robinson, T. M., Towlerton, A. M. H., Warren, E. H., Zeidner, J. F., Blackford, A. L., Duffield, A. S., Rizzieri, D. A., Frattini, M. G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3763 · Cited by 102
Self-citationSun, H. Q., Li, Y., Zhang, Z., Ju, Y., Li, L., Zhang, B., & Liu, B. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1865-2 · Cited by 99
Guillaume, T., Malard, F., Magro, L., Labopin, M., Tabrizi, R., Borel, C., Chevallier, P., Vigouroux, S., Péterlin, P., Garnier, A., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0536-y · Cited by 99
Li, L., Giannopoulos, K., Reinhardt, P., Tabarkiewicz, J., Schmitt, A., Greiner, J., Roliński, J., Hus, I., Dmoszyńska, A., Wiesneth, M., et al. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.4.855 · Cited by 97
Sekeres, M. A., Lancet, J. E., Wood, B. L., Grove, L. E., Sandalic, L., Sievers, E. L., & Jurcic, J. G. (2012) · Haematologica · doi:10.3324/haematol.2012.066613 · Cited by 96
Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680546 · Cited by 93
Tan, J., Chen, S., Lu, Y., Yao, D., Xu, L., Zhang, Y., Yang, L., Chen, J., Lai, J., Yu, Z. H., et al. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.05.11 · Cited by 93
van de Loosdrecht, A. A., van Wetering, S., Santegoets, S. J. A. M., Singh, S., Eeltink, C., den Hartog, Y. M., Koppes, M., Kaspers, J., Ossenkoppele, G. J., Kruisbeek, A. M., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2198-9 · Cited by 92
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
Giacomo, A. M. D., Covre, A., Finotello, F., Rieder, D., Danielli, R., Sigalotti, L., Giannarelli, D., Petitprez, F., Lacroix, L., Valente, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1335 · Cited by 89
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
Goswami, M., Gui, G., Dillon, L. W., Lindblad, K. E., Thompson, J., Valdez, J., Kim, D., Ghannam, J. Y., Oetjen, K. A., DeStefano, C. B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003392 · Cited by 88
Borate, U., Esteve, J., Porkka, K., Knapper, S., Vey, N., Scholl, S., Garcia‐Manero, G., Wermke, M., Janssen, J., Traer, E. A., et al. (2019) · Blood · doi:10.1182/blood-2019-128178 · Cited by 86
Laborda, E., Mazagova, M., Shao, S., Wang, X., Quirino, H., Woods, A. C., Hampton, E. N., Rodgers, D. T., Kim, C., Schultz, P. G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112259 · Cited by 84
Li, S., Tao, Z., Xu, Y., Liu, J., An, N., Wang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.241 · Cited by 84
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
Laszlo, G. S., Gudgeon, C. J., Harrington, K. H., & Walter, R. B. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.68 · Cited by 82
Zeidan, A. M., Cavenagh, J. D., Voso, M. T., Taussig, D. C., Tormo, M., Boss, I. W., Copeland, W. B., Gray, V. E., Previtali, A., O'Connor, T., et al. (2019) · Blood · doi:10.1182/blood-2019-122896 · Cited by 79
CD40 ligation reverses T cell tolerance in acute myeloid leukemia
Zhang, L., Chen, X., Liu, X., Kline, D. E., Teague, R. M., Gajewski, T. F., & Kline, J. P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63980 · Cited by 76
Siegel, S., Wagner, A., Kabelitz, D., Marget, M., Coggin, J. H., Barsoum, A. L., Rohrer, J. W., Schmitz, N., & Zeis, M. (2003) · Blood · doi:10.1182/blood-2003-01-0198 · Cited by 76
Qazilbash, M. H., Wieder, E., Rios, R., et al. (2004) · Blood · doi:10.1182/blood.v104.11.259.259 · Cited by 71
Brodská, B., Otevřelová, P., Šálek, C., Fuchs, O., Gašová, Z., & Kuželová, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112823 · Cited by 71
Gojo, I., Stuart, R. K., Webster, J. A., Blackford, A. L., Varela, J. C., Morrow, J., Dezern, A. E., Foster, M. C., Levis, M. J., Coombs, C. C., et al. (2019) · Blood · doi:10.1182/blood-2019-127345 · Cited by 71
Self-citationImmune evasion by oncogenic proteins of acute myeloid leukemia
Elias, S., Yamin, R., Golomb, L., Tsukerman, P., Stanietsky, N., Ben‐Yehuda, D., & Mandelboim, O. (2014) · Blood · doi:10.1182/blood-2013-09-526590 · Cited by 69
Yöyen-Ermiş, D., Tunalı, G., Tavukçuoğlu, E., Horzum, U., Özkazanç, D., Sütlü, T., Büyükaşık, Y., & Esendağlı, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-48256-4 · Cited by 65
Daver, N. G., Montesinos, P., DeAngelo, D. J., Wang, E. S., Papadantonakis, N., Deconinck, É., Erba, H. P., Pemmaraju, N., Lane, A. A., Rizzieri, D. A., et al. (2019) · Blood · doi:10.1182/blood-2019-128648 · Cited by 63
Adamia, S., Bar‐Natan, M., Haibe‐Kains, B., Pilarski, P. M., Bach, C., Pevzner, S. J., Calimeri, T., Avet‐Loiseau, H., Lodé, L., Verselis, S. J., et al. (2014) · Blood · doi:10.1182/blood-2013-02-481507 · Cited by 62
Raza, A., Jurcic, J. G., Roboz, G. J., Maris, M. B., Stephenson, J. J., Wood, B. L., Feldman, E. J., Galili, N., Grove, L. E., Drachman, J. G., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903050013 · Cited by 61
Graft versus tumor effects and why people relapse
Falkenburg, J. H. F., & Jedema, I. (2017) · Hematology · doi:10.1182/asheducation-2017.1.693 · Cited by 59
Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Veomett, N. J., Dao, T., Liu, H., Xiang, J., Pankov, D., Dubrovsky, L., Whitten, J. A., Park, S., Korontsvit, T., Zakhaleva, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2756 · Cited by 55
Ravandi, F., Bashey, A., Foran, J. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119786 · Cited by 55
Vaccine therapy in hematologic malignancies
Avigan, D., & Rosenblatt, J. M. (2018) · Blood · doi:10.1182/blood-2017-11-785873 · Cited by 54
Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Knaus, H. A., Kanakry, C. G., Luznik, L., & Gojo, I. (2017) · Current Drug Targets · doi:10.2174/1389450116666150518095346 · Cited by 51
Self-citationThe role of leukemia-derived B7-H1 (PD-L1) in tumor–T-cell interactions in humans
Salih, H. R., Wintterle, S., Krusch, M., Kroner, A., Huang, Y.-H., Chen, L., & Wiendl, H. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.03.006 · Cited by 50
Radpour, R., Riether, C., Simillion, C., Höpner, S., Bruggmann, R., & Ochsenbein, A. F. (2019) · Leukemia · doi:10.1038/s41375-019-0441-9 · Cited by 48
Fozza, C., Corda, G., Barraqueddu, F., Virdis, P., Contini, S., Galleu, A., Isoni, A., Dore, F., Angelucci, E., & Longinotti, M. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.06.007 · Cited by 44
Fukuno, K., Hara, T., Tsurumi, H., Shibata, Y., Mabuchi, R., Nakamura, N., Kitagawa, J., Shimizu, M., Ito, H., Saito, K., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.953150 · Cited by 44
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Kadia, T. M., Cortes, J. E., Ghorab, A., Ravandi, F., Jabbour, E. J., Daver, N. G., Alvarado, Y., Ohanian, M. N., Konopleva, M. Y., & Kantarjian, H. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.7014 · Cited by 43
Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia
Ismail, M. M., & Abdulateef, N. A. B. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2153-5 · Cited by 42
Gong, J., Koido, S., Kato, Y., Tanaka, Y., Chen, D., Jonas, A. K., Galinsky, I. A., DeAngelo, D. J., Avigan, D., Kufe, D. W., et al. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.03.018 · Cited by 37
Očadlíková, D., Lecciso, M., Isidori, A., Loscocco, F., Visani, G., Amadori, S., Cavo, M., & Curti, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01004 · Cited by 37
CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell Fates
Kline, D. E., MacNabb, B. W., Chen, X., Chan, W., Fosco, D., & Kline, J. P. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1801184 · Cited by 34
Sandri, S., Sanctis, F. D., Lamolinara, A., Boschi, F., Poffe, O., Trovato, R., Fiore, A., Sartori, S., Sbarbati, A., Bondanza, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18115 · Cited by 31
Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens
Lansford, J. L., Dharmasiri, U., Chai, S., Hunsucker, S. A., Bortone, D. S., Keating, J. E., Schlup, I. M., Glish, G. L., Collins, E. J., Alatrash, G., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022475 · Cited by 29
Sallman, D. A., Brayer, J. B., Poiré, X., Havelange, V., Awada, A. H., Lewalle, P., Odunsi, K. O., Wang, E. S., Lonez, C., Lequertier, T., et al. (2019) · Blood · doi:10.1182/blood-2019-128020 · Cited by 27
Expression of CD 274 ( PD ‐L1) is associated with unfavourable recurrent mutations in AML
Zajac, M., Zaleska, J., Dolnik, A., Bullinger, L., & Giannopoulos, K. (2017) · British Journal of Haematology · doi:10.1111/bjh.15040 · Cited by 20
Xiao, W., Goldberg, A. D., Famulare, C. A., Devlin, S. M., Nguyen, N. T., Sim, S., Kabel, C. C., Patel, M. A., McGovern, E. M., Patel, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.203018 · Cited by 20
Novel monoclonal antibody-based therapies for acute myeloid leukemia
Morsink, L. M., & Walter, R. B. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.002 · Cited by 19
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting
Penter, L., & Wu, C. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129209 · Cited by 19
Salman, A., Kopardé, V. N., Hall, C. E., Jameson‐Lee, M., Roberts, C. H., Serrano, M. G., Razzaq, B. A., Meier, J. A., Kennedy, C. J., Manjili, M. H., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02284 · Cited by 17
Rutella, S., Church, S., Vadakekolathu, J. N., Viboch, E., Sullivan, A. H., Hood, T., Warren, S. E., Cesano, A., Motte-Mohs, R. N. L., MUTH, J. B., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111539 · Cited by 14
Wong, E. Y. L., Dawson, E., Davis, J. E., Koldej, R. M., Ludford‐Menting, M., Lansdown, M., Lambie, H., Szer, J., Grigg, A., & Ritchie, D. (2018) · Blood · doi:10.1182/blood-2018-99-112310 · Cited by 12
Cited by
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Song, Y., Zhang, L., Wang, Y., Han, M., Wang, Z., Wang, N., Shao, B., Li, R., Cao, K., Song, M., et al. (2023) · Advanced Materials · doi:10.1002/adma.202210895 · Cited by 54
Metadata
- Authors
- Vago, L., & Gojo, I.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-04-01
- Volume
- 130
- Issue
- 4
- Pages
- 1552-1564
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3014109498
- Cited by
- 341
- References
- 165
- FWCI
- 21.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.